Biotechnology Law Report

Papers
(The TQCC of Biotechnology Law Report is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Continuing CRISPR Patent Disputes May Be Usurped by Its Potential Role in Fighting Global Pandemics9
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Regulation of Artificial Intelligence in Drug Discovery and Health Care3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy3
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines2
UK Biotech Corporate Finance Trends Post COVID-192
GlaxoSmithKline v. Teva: Holding a Generic Liable for an Artificial Act of Inducement2
Legal and Ethical Challenges in the Construction of China's Biobanks2
Legitimacy of Experimental Use of Patented Research Tools by Chinese Universities2
Exclusions from Patentability with an Emphasis on Biotechnological Inventions: A Comparative Study1
Idorsia Pharmaceuticals, Ltd. v. Iancu United States Court of Appeals of the Federal Circuit, 2020 811 Fed. Appx. 650 (nonprecedential)1
State Universities Push the Limits of Eleventh Amendment Sovereign Immunity at the Federal Circuit1
Arbitrability of Disputes Arising from Patents: A Comparative Study1
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13711
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR1
Myco Indus., Inc. v. BlephEx, LLC United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 11
Par Pharm., Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1273, 2020 WL 6846347 (Non-precedential)1
Genentech, Inc. v. Immunex Rhode Island Corp. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 11091
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Hospira, Inc. v. Fresenius Kabi USA, LLC United States Court of Appeals of the Federal Circuit, 2020 946 F.3d 13221
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)1
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Introduction on Biosafety Law of the People's Republic of China and Linkage Thereof with International and Domestic Regulations1
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.1
Legislative Moves on Biosecurity in China1
Par Pharm., Inc. v. Eagle Pharms., Inc.1
Novartis Pharms. Corp. v. Accord Healthcare, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
AstraZeneca AB v. Mylan Pharms. Inc.1
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich1
Horizon Pharma, Inc. v. Dr. Reddy's Labs. Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-1607, 2021 WL 48428 (Non-precedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10801
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Dana-Farber Cancer Inst., Inc. v. Ono Pharm. Co. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 13651
Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Eagle Pharm. Inc. v. Slayback Pharma LLC United States Court of Appeals of the Federal Circuit, 2020 958 F.3d 11711
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9641
Biogen Int'l GmbH v. Banner Life Scis. LLC United States Court of Appeals of the Federal Circuit, 2020 956 F.3d 13511
A Review of Patent Regimes on Health Biotechnology Innovation in India1
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13551
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I1
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13301
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Univ. of Massachusetts v. L'Oreal S.A.1
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine1
Valeant Pharm. Int'l, Inc. v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 251
Bio-Rad Labs., Inc. v. 10X Genomics Inc. United States Court of Appeals of the Federal Circuit, 2020 967 F.3d 13531
Hologic, Inc. v. Minerva Surgical, Inc. United States Court of Appeals of the Federal Circuit, 2020 957 F.3d 12561
Genentech, Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 946 F.3d 13331
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods1
Biogen MA Inc. v. EMD Serono, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13261
Verinata Health, Inc. v. Ariosa Diagnostics, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2018-2198, 2020 WL 1970571 (Nonprecedential)1
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies1
XY, LLC v. Trans Ova Genetics, LC United States Court of Appeals of the Federal Circuit, 2020 968 F.3d 13231
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
Vectura Ltd. v. Glaxosmithkline LLC. United States Court of Appeals of the Federal Circuit, 2020 981 F.3d 10301
Ferring B.V. v. Allergan, Inc. United States Court of Appeals of the Federal Circuit, 2020 980 F.3d 8411
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control1
Eli Lilly & Co. v. Apotex, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1328, 2020 WL 7490251 (Non-precedential)1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
0.02634596824646